Last updated on May 2019

Survey Study for Velaglucerase Alfa (VPRIV) in Japan


Brief description of study

The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or have been switched from another therapeutic agent for Gaucher disease.

Clinical Study Identifier: NCT03625882

Find a site near you

Start Over

Nagoya

Nagoya, Japan
1.88miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.